Endocrine, Metabolic & Immune Disorders - Drug Targets (EMIDDT)

Endocrine, Metabolic & Immune Disorders-Drug Targets is an international, peer-reviewed scientific journal devoted to advancing knowledge on molecular and clinical aspects of disorders driven by endocrine hormones, metabolic dysfunction and immune dysregulation. It serves researchers, clinicians, pharmacologists and drug developers by publishing high-quality reviews and original studies on novel drug targets, mechanisms of action, and therapeutic strategies for complex diseases such as diabetes, obesity, autoimmune endocrine diseases, metabolic syndrome, thyroid disorders and related inflammatory conditions. The journal emphasizes the identification and validation of druggable targets at the cellular, genetic and systemic level, including the impact of nutraceuticals, biologics and engineered therapeutics on endocrine-metabolic-immune pathways. Emerging topics like gut-microbiota interactions in metabolic disease and precision medicine approaches are also included. With indexing in major databases such as MEDLINE/PubMed, Scopus and Science Citation Index Expanded, Endocrine, Metabolic & Immune Disorders-Drug Targets publishes evidence-based insights that bridge basic science and clinical applications. It is an essential forum for multidisciplinary research addressing the pathophysiology and treatment of diseases where endocrine, metabolic and immune systems intersect.

Endocrine, Metabolic & Immune Disorders - Drug Targets (EMIDDT) is :-

• International, Peer-Reviewed, Open Access, Refereed, General Medicine, Endocrinology, Diabetes and Metabolism, Immunology and Allergy , Online or Print , Bi-Annual Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1871-5303, E-ISSN: 2212-3873, Established: 2006, Impact Factor: 2
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE